摘要
免疫治疗作为当前最热门的治疗研究领域之一,在诸多系统肿瘤临床试验中证实疗效显著。程序性死亡配体1(PD-L1)是一种参与免疫抑制通路的分子,在较多实体肿瘤细胞及其周围T淋巴细胞表面显著表达,能与其受体程序性死亡受体1(PD-1)结合,抑制肿瘤组织周围的免疫微环境,促进肿瘤细胞的恶化。PD-1/PD-L1的表达不仅与患者的预后及临床分期具有一定的相关性,同时还有望成为独立的临床生物标志物,进而为肿瘤的免疫治疗提供新的靶点。
As one of the most popular therapeutic studies ,immunotherapy has proved effective in many systemic tumor chnical trials. Programmed death ligand 1 （PD-L1） is a molecule involved in immunosuppression pathway, significantly expressed on the surface of plenty of solid tumor cells and the peripheral T lymphocytes, which can combine with pro- grammed death receptor 1 （ PD-1 ）, inhibit the immune microenvironment around tumor tissue, and promote the deterioration of the tumor ceils. PD-1/PD-L1 expression is not only associated with the prognosis of patients and clinical staging,but is also expected to become an independent clinical biomarker, and provides new target for tumor immunotherapy.
作者
范钰
刘斌
钱震
袁会军
李甜甜
FAN YU LIU Bin Q IAN Zhen YUAN Huijun LI Tiantian.(Department of Pathology , Lanzhou General Hospital , Lanzhou 730050, Chin)
出处
《医学综述》
2017年第18期3590-3594,共5页
Medical Recapitulate
